Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


3 AJR Am J Roentgenol
1 Ann Surg Oncol
3 Ann Thorac Surg
3 BMC Cancer
1 Cancer Cell
1 Cancer Res
2 Clin Cancer Res
5 Clin Lung Cancer
6 Int J Cancer
3 J Clin Oncol
1 J Nucl Med
4 J Surg Oncol
3 J Thorac Cardiovasc Surg
1 JAMA Oncol
1 Lancet
3 Lung Cancer
2 Oncologist
2 PLoS One
1 Science

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. SERAI SD, Rapp JB, States LJ, Andronikou S, et al
    Pediatric Lung MRI: Currently Available and Emerging Techniques.
    AJR Am J Roentgenol. 2021 Jan 21:1-10. doi: 10.2214/AJR.20.23104.
    PubMed         Abstract available

  2. JI Y, Shao CC, Cui Y, Cui K, et al
    The Diagnostic Value of FDG PET/CT and Thin-Slice High-Resolution Chest CT in Pulmonary Intravascular Metastasis.
    AJR Am J Roentgenol. 2021 Jan 6:1-7. doi: 10.2214/AJR.20.23017.
    PubMed         Abstract available

  3. LEE GM, Stowell JT, Pope K, Carter BW, et al
    Lymphatic Pathways of the Thorax: Predictable Patterns of Spread.
    AJR Am J Roentgenol. 2021;216:649-658.
    PubMed         Abstract available

    Ann Surg Oncol

  4. ZHU Y, Liu L
    ASO Author Reflections: A Novel Concept to Decreasing the Technical Difficulty of Complex Pulmonary Segmentectomy.
    Ann Surg Oncol. 2020;27:3094-3095.

    Ann Thorac Surg

  5. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Oncologic Outcomes of Complex Segmentectomy: A Multicenter Propensity Score-Matched Analysis.
    Ann Thorac Surg. 2021;111:1044-1051.
    PubMed         Abstract available

  6. VOSSLER JD, Abdul-Ghani A, Tsai PI, Morris PT, et al
    Outcomes of Anatomic Lung Resection for Cancer Are Better When Performed by Cardiothoracic Surgeons.
    Ann Thorac Surg. 2021;111:1004-1011.
    PubMed         Abstract available

  7. LI AX, Flores K, Canavan ME, Boffa DJ, et al
    Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules.
    Ann Thorac Surg. 2021 Mar 5. pii: S0003-4975(21)00424.
    PubMed         Abstract available

    BMC Cancer

  8. TSUCHIYA T, Matsumoto K, Miyazaki T, Doi R, et al
    A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study.
    BMC Cancer. 2021;21:249.
    PubMed         Abstract available

  9. LI H, Ding L, Hong X, Chen Y, et al
    Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.
    BMC Cancer. 2021;21:259.
    PubMed         Abstract available

  10. PROVENCIO M, Terrasa J, Garrido P, Campelo RG, et al
    Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    BMC Cancer. 2021;21:230.
    PubMed         Abstract available


  11. DYER O
    US task force recommends extending lung cancer screenings to over 50s.
    BMJ. 2021;372:n698.

    Cancer Cell

  12. LAFAVE LM, Kartha VK, Ma S, Meli K, et al
    Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma.
    Cancer Cell. 2020;38:212-228.
    PubMed         Abstract available

    Cancer Res

  13. YANG Z, Liang SQ, Yang H, Xu D, et al
    CRISPR-mediated kinome editing prioritizes a synergistic combination therapy for FGFR1-amplified lung cancer.
    Cancer Res. 2021 Mar 8. pii: 0008-5472.CAN-20-2276.
    PubMed         Abstract available

    Clin Cancer Res

  14. BLAKELY CM, McCoach CE
    Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
    Clin Cancer Res. 2020;26:3499-3500.
    PubMed         Abstract available

  15. LIN JJ, Choudhury NJ, Yoda S, Zhu VW, et al
    Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
    Clin Cancer Res. 2021 Mar 8. pii: 1078-0432.CCR-21-0032.
    PubMed         Abstract available

    Clin Lung Cancer

  16. LIN X, Jiao H, Pang Z, Chen H, et al
    Lung Cancer and Granuloma Identification Using a Deep Learning Model to Extract 3-Dimensional Radiomics Features in CT Imaging.
    Clin Lung Cancer. 2021 Feb 6. pii: S1525-7304(21)00027.
    PubMed         Abstract available

  17. SHINTANI T, Kishi N, Matsuo Y, Ogura M, et al
    Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00020.
    PubMed         Abstract available

  18. GOULART BHL, Chennupati S, Fedorenko CR, Ramsey SD, et al
    Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR(+) and ALK(+) Positive Non-small-cell Lung Cancer Treated in the Real-World.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00022.
    PubMed         Abstract available

  19. BOYCE-FAPPIANO D, Nguyen QN, Chapman BV, Allen PK, et al
    Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Feb 7. pii: S1525-7304(21)00025.
    PubMed         Abstract available

  20. KERRIGAN K, Wang X, Haaland B, Adamson B, et al
    Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.
    Clin Lung Cancer. 2021 Jan 26. pii: S1525-7304(21)00016.
    PubMed         Abstract available

    Int J Cancer

  21. FU F, Zhang Y, Gao Z, Zhao Y, et al
    Development and Validation of a Five-Gene Model to Predict Postoperative Brain Metastasis in Operable Lung Adenocarcinoma.
    Int J Cancer. 2020 Mar 17. doi: 10.1002/ijc.32981.
    PubMed         Abstract available

  22. DAGNINO S, Bodinier B, Grigoryan H, Rappaport SM, et al
    Agnostic Cys34-albumin adductomics and DNA methylation: Implication of N-acetylcysteine in lung carcinogenesis years before diagnosis.
    Int J Cancer. 2020;146:3294-3303.
    PubMed         Abstract available

  23. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed         Abstract available

  24. VAN DER WILLIK KD, Ruiter R, van Rooij FJA, Verkroost-van Heemst J, et al
    Ascertainment of cancer in longitudinal research: The concordance between the Rotterdam Study and the Netherlands Cancer Registry.
    Int J Cancer. 2020;147:633-640.
    PubMed         Abstract available

  25. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed         Abstract available

  26. URAKAWA H, Ando Y, Hase T, Kikumori T, et al
    Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
    Int J Cancer. 2020;146:3504-3515.
    PubMed         Abstract available

    J Clin Oncol

  27. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.

  28. RUSTHOVEN CG, Camidge DR, Robin TP, Brown PD, et al
    Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.
    J Clin Oncol. 2020 Aug 10:JCO2001823. doi: 10.1200/JCO.20.01823.

  29. OWONIKOKO TK, Park K, Govindan R, Ready N, et al
    Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
    J Clin Oncol. 2021 Mar 8:JCO2002212. doi: 10.1200/JCO.20.02212.
    PubMed         Abstract available

    J Nucl Med

  30. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed         Abstract available

    J Surg Oncol

  31. DUAN XQ, Wang XL, Zhang LF, Liu XZ, et al
    Establishment and validation of a prediction model for the probability of malignancy in solid solitary pulmonary nodules in northwest China.
    J Surg Oncol. 2021;123:1134-1143.
    PubMed         Abstract available

  32. FELDMAN HA, Zhou N, Antonoff MB, Hofstetter WL, et al
    Simultaneous versus staged resections for bilateral pulmonary metastases.
    J Surg Oncol. 2021 Mar 8. doi: 10.1002/jso.26392.
    PubMed         Abstract available

  33. SONODA D, Matsuura Y, Kondo Y, Ichinose J, et al
    Comparison of local therapy in patients with lung oligo-recurrence of non-small-cell lung cancer.
    J Surg Oncol. 2021 Mar 8. doi: 10.1002/jso.26453.
    PubMed         Abstract available

  34. VIDARSDOTTIR H, Siesing C, Nodin B, Jonsson P, et al
    Clinical significance of RBM3 expression in surgically treated colorectal lung metastases and paired primary tumors.
    J Surg Oncol. 2021;123:1144-1156.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  35. IMAI T, Weksler B
    Commentary: Eurolung score as a predictor of long-term survival: It is not all about the tumor.
    J Thorac Cardiovasc Surg. 2021;161:788-789.

    Commentary: We need more surgeons!
    J Thorac Cardiovasc Surg. 2021;161:804-805.

  37. TONG BC
    Commentary: Safety first!
    J Thorac Cardiovasc Surg. 2021;161:803-804.

    JAMA Oncol

  38. ITO FUKUNAGA M, Wiener RS, Slatore CG
    The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same....
    JAMA Oncol. 2021 Mar 9. pii: 2777056. doi: 10.1001/jamaoncol.2020.8376.


  39. BAAS P, Scherpereel A, Nowak AK, Fujimoto N, et al
    First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2021;397:375-386.
    PubMed         Abstract available

    Lung Cancer

  40. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
    Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.

  41. KERR KM, Bibeau F, Thunnissen E, Botling J, et al
    The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Lung Cancer. 2021;154:161-175.
    PubMed         Abstract available

  42. ATTILI I, Tarantino P, Passaro A, Stati V, et al
    Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Lung Cancer. 2021;154:151-160.
    PubMed         Abstract available


  43. RODRIGUEZ-ANTOLIN C, Rosas-Alonso R, Cruz P, Higuera O, et al
    Novel SLC12A2-ROS1 fusion in non-small-cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay.
    Oncologist. 2021 Mar 8. doi: 10.1002/onco.13745.
    PubMed         Abstract available

  44. MATHIEU L, Shah S, Pai-Scherf L, Larkins E, et al
    FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Oncologist. 2021 Mar 9. doi: 10.1002/onco.13752.
    PubMed         Abstract available

    PLoS One

  45. YU G, Cai Q, Xu X, Shen Y, et al
    Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
    PLoS One. 2021;16:e0247494.
    PubMed         Abstract available

  46. BURNETT H, Emich H, Carroll C, Stapleton N, et al
    Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
    PLoS One. 2021;16:e0247620.
    PubMed         Abstract available


  47. QUINN JJ, Jones MG, Okimoto RA, Nanjo S, et al
    Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts.
    Science. 2021;371.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.